Mateusz Kaczmarek

Mateusz Kaczmarek is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, semiconductors and global market developments. A graduate of the Poznań University of Economics and Business, he previously worked in financial analysis before moving into business journalism. His reporting focuses on technology companies, market trends and the forces shaping global investment markets. Follow Mateusz Kaczmarek on Google News.

Light & Wonder (ASX:LNW) Completes Nasdaq Delisting, Fires Up A$10.8bn ASX Era With New Mega Buyback

Light & Wonder (ASX:LNW) Completes Nasdaq Delisting, Fires Up A$10.8bn ASX Era With New Mega Buyback

Light & Wonder, Inc. has officially left the Nasdaq and begun life as a sole listing on the Australian Securities Exchange, wrapping the move in a suite of shareholder‑friendly measures – including a huge new on‑market buyback, fresh governance documents, and an updated employee stock purchase plan effective today. IAG+2LNW Explore+2
14 November 2025
···
Opendoor (OPEN) Stock News Today – AI Pivot, $1M CEO Buy and Q3 Earnings Put Meme Favorite Back Under the Microscope

Opendoor (OPEN) Stock News Today – AI Pivot, $1M CEO Buy and Q3 Earnings Put Meme Favorite Back Under the Microscope

Opendoor Technologies Inc. is back in the market spotlight today as a flood of fresh coverage dissects its high‑stakes AI pivot, a $1 million insider stock purchase, and the lingering fallout from weak third‑quarter results — all against the backdrop of a meme‑fueled rally that has sent the stock from penny‑stock territory to around $8–9 a share this year. Google+2TradingView+2
14 November 2025
··
Applied Digital (APLD) Prices $2.35 Billion Notes as AI Data Center Expansion Meets Market Jitters

Applied Digital (APLD) Prices $2.35 Billion Notes as AI Data Center Expansion Meets Market Jitters

Applied Digital Corporation, one of the fastest‑growing AI data‑center names on the Nasdaq, is back in focus today after pricing a massive $2.35 billion senior secured notes offering designed to supercharge its North Dakota “AI Factory” buildout. The financing arrives just days after the company lined up up to $787.5 million in additional equity funding from Macquarie Asset Management, but the stock is still suffering one of its roughest weeks in nearly two years as investors weigh leverage, dilution and broader AI anxiety. Applied Digital Corporation+2Applied Digital Corporation+2
14 November 2025
·
TSS Inc. (TSSI) Stock Plunges Over 40% After Q3 2025 Earnings – AI Pivot, New Dell Veteran Director and What’s Next for 2026

TSS Inc. (TSSI) Stock Plunges Over 40% After Q3 2025 Earnings – AI Pivot, New Dell Veteran Director and What’s Next for 2026

TSS, Inc., the AI‑focused data center systems integrator, is at the center of a dramatic market move today. Shares are trading in the high single digits this afternoon, down a little over 40% from yesterday’s close around $15.25, after investors digested a sharp Q3 2025 revenue decline, a swing to loss, and a simultaneously raised full‑year profit outlook. Finimize
14 November 2025
···
Fastenal (FAST) Stock on 14 November 2025: New CFO, Barclays Price Target Cut to $44, and Fresh Undervaluation Debate

Fastenal (FAST) Stock on 14 November 2025: New CFO, Barclays Price Target Cut to $44, and Fresh Undervaluation Debate

Fastenal Company is under the spotlight again as investors digest a wave of fresh headlines: a new analysis arguing the stock may be potentially undervalued, a new chief financial officer stepping in, multiple analyst downgrades and price-target cuts, plus big institutional and insider buying in the background. Investing.com UK+4Yahoo Finance+4Fastenal Investor+4
14 November 2025
·
1 … 49 50 51 52 53 … 164

Stock Market Today

  • Revolution Medicines (RVMD) Shares Trade at a Premium Despite Robust Gains
    July 25, 2026, 2:47 PM EDT. Revolution Medicines (RVMD) shares have jumped with a 399.2% return over the past year and approximately 6.4x growth in three years, though the stock's valuation is considered steep. With a P/B ratio of 26.8x, Revolution Medicines is well above the Biotech sector's 2.5x average and peer level of 10.3x. The stock meets just 2 out of 6 valuation criteria, indicating a premium linked to its FDA-reviewed drug daraxonrasib and data from its pancreatic cancer trial, along with concerns tied to regulatory risk.